9U9 Stock Overview
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Unity Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$2.88 |
| 52 Week Low | US$1.35 |
| Beta | 0.87 |
| 1 Month Change | 5.03% |
| 3 Month Change | -8.39% |
| 1 Year Change | n/a |
| 3 Year Change | -96.66% |
| 5 Year Change | n/a |
| Change since IPO | -98.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9U9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.2% | -4.9% | -1.5% |
| 1Y | n/a | -19.9% | 0.9% |
Return vs Industry: Insufficient data to determine how 9U9 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 9U9 performed against the German Market.
Price Volatility
| 9U9 volatility | |
|---|---|
| 9U9 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9U9's share price has been volatile over the past 3 months.
Volatility Over Time: 9U9's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Anirvan Ghosh | unitybiotechnology.com |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology, Inc. Fundamentals Summary
| 9U9 fundamental statistics | |
|---|---|
| Market cap | €23.73m |
| Earnings (TTM) | -€37.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 9U9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9U9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$20.10m |
| Gross Profit | -US$20.10m |
| Other Expenses | US$19.76m |
| Earnings | -US$39.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9U9 perform over the long term?
See historical performance and comparison